Fu-Long Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fu-Long Li has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Adam Jeffrey Engler
Chien-Lay Department of Bioengineering, UC San Diego, San Diego, California, USA
1 shared publication - Benjamin Yeoman
Department of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA
1 shared publication - Bing Ren
New York Genome Center; New York, NY, USA
1 shared publication Cao Fang
Department of Pharmacology and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA
1 shared publication- Di Yang
Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas
1 shared publication - Filippo G. Giancotti
Cancer Metastasis Initiative, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA
1 shared publication
Latest Publications
- Open Access
- 27 May 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (21) , eabl9806
The Hippo pathway mediates Semaphorin signaling
Semaphorins were originally identified as axonal guidance molecules, but they also control processes such as vascular development and tumorigenesis. The downstream signaling cascades of Semaphorins in these biological processes remain unclear. Here, we show that the class 3 Semaphorins (SEMA3s) activate the Hippo pathway to attenuate tissue growth, angiogenesis, and tumorigenesis. SEMA3B restoration in lung cancer cells with SEMA3B loss of heterozygosity suppresses cancer cell growth via activating the core Hippo kinases LATS1/2 (large tumor suppressor kinase 1/2). Furthermore, SEMA3 also acts through LATS1/2 to inhibit angiogenesis. We identified p190RhoGAPs as essential partners of the SEMA3A receptor PlexinA in Hippo regulation. Upon SEMA3 treatment, PlexinA interacts with the pseudo–guanosine triphosphatase (GTPase) domain of p190RhoGAP and simultaneously recruits RND GTPases to activate p190RhoGAP, which then stimulates LATS1/2. Disease-associated etiological factors, such as genetic lesions and oscillatory shear, diminish Hippo pathway regulation by SEMA3. Our study thus discovers a critical role of Hippo signaling in mediating SEMA3 physiological function.
- 27 May 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (21) , eabl9806
Open AccessThe Hippo pathway mediates Semaphorin signaling
Semaphorins were originally identified as axonal guidance molecules, but they also control processes such as vascular development and tumorigenesis. The downstream signaling cascades of Semaphorins in these biological processes remain unclear. Here, we show that the class 3 Semaphorins (SEMA3s) activate the Hippo pathway to attenuate tissue growth, angiogenesis, and tumorigenesis. SEMA3B restoration in lung cancer cells with SEMA3B loss of heterozygosity suppresses cancer cell growth via activating the core Hippo kinases LATS1/2 (large tumor suppressor kinase 1/2). Furthermore, SEMA3 also acts through LATS1/2 to inhibit angiogenesis. We identified p190RhoGAPs as essential partners of the SEMA3A receptor PlexinA in Hippo regulation. Upon SEMA3 treatment, PlexinA interacts with the pseudo–guanosine triphosphatase (GTPase) domain of p190RhoGAP and simultaneously recruits RND GTPases to activate p190RhoGAP, which then stimulates LATS1/2. Disease-associated etiological factors, such as genetic lesions and oscillatory shear, diminish Hippo pathway regulation by SEMA3. Our study thus discovers a critical role of Hippo signaling in mediating SEMA3 physiological function.